Challenging Cases in the Management of Acromegaly
Challenging Cases in the Management of Acromegaly
Saturday, March 7, 2015 | 6:30 – 9:30 PM PST
Hilton San Diego Bayfront Hotel, Sapphire Ballroom B
This course is a live CME-certified ancillary symposium presented at ENDO 2015, the Endocrine Society's 97th Annual Meeting and Expo, held in San Deigo, California, March 5–8, 2015. ENDO 2015 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2015 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2015 to attend an ENDO 2015 ancillary symposium.
This activity is supported by an educational grant from Novartis Pharmaceuticals Cooperation.
Welcome and Introduction
Program Director: John A. H. Wass, MD – University of Oxford (UK)
Challenges in Diagnosis and Monitoring
John A. H. Wass, MD – University of Oxford (UK)
Update on the Medical Management of Acromegaly
Monica Gadelha, MD – Instituto Estadual do Cérebro Paulo Niemeyer (Brazil)
Challenges to Minimize Comorbidities and Improving Quality of Life
Mark Molitch, MD - Northwestern University Feinberg School of Medicine
This program should be of substantial interest to: endocrinologists and endocrine fellows with additional interest from primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals caring for individuals with acromegaly or pituitary adenomas.
Upon completion of this educational activity, participants will better able to:
- Apply updated guidelines in the screening for acromegaly and monitoring treatment outcomes using biochemical assays
- Select among medical management options for the treatment of acromegaly taking into consideration efficacy, side effects, and combination strategies
- Recognize morbidities of acromegaly and devise strategies to prevent and treat in long-term management
John A. H. Wass, MD – Program Director
Professor of Endocrinology
Oxford Center for Diabetes, Endocrinology and Metabolism
University of Oxford
Oxford, United Kingdom
Monical Gadelha, MD, PhD
Instituto Estadual do Cérebro Paulo Niemeyer
Division of Endocrinology
Rio de Janeiro, Brazil
Mark Molitch, MD
Martha Leland Sherwin Professor of Endocrinology
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships:
Monica Gadelha, MD: Advisory Board Member, Consultant, Research Grant Support and Speaker, Novartis Pharmaceuticals; Principal Invesgator and Speaker, Ipsen; Research Grant Support, Pfizer, Inc.
Mark Molitch, MD: Advisory Board Member, Chiasma; Consultant, Pfizer, Inc.; Investigator, Ipsen, Novartis Pharmaceuticals
The following faculty reported no relevant financial relationships: John AH Wass, MD
The following SPC member who planned and reviewed content for this activity reported relevant financial relationships:
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
The following SPC Committee members reported relevant financial relationships:
Sarah Berga, MD: Advisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl B. Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck;
Anton Luger, MD: Advisory Board Member, Investigator and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E. Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron
Andrea L. Utz, MD, PhD: Investigator, Corcept, Ipsen
The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Larry Fox, MD; Michael S. Irwig, MD; Connie B Newman, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
- 2.50 AMA PRA Category 1 Credits™
- 2.50 CME Certificate of Participation